论文部分内容阅读
目的探讨替米沙坦联合瑞舒伐他汀对T2DM合并冠心病患者血清肝细胞生长因子(HGF)及其受体(c-met)和PPAR-γ表达水平的影响。方法选取95例T2DM合并冠心病患者,将其分为对照组、替米沙坦组和替米沙坦联合瑞舒伐他汀组。检测各组血清HGF、c-met和PPAR-γ水平。结果与对照组比较,替米沙坦组、替米沙坦联合瑞舒伐他汀组治疗后HGF[(338.96±36.51)vs(241.56±29.88)vs(173.23±32.25)pg/ml]、c-met[(0.657±0.162)vs(0.489+0.093)vs(0.247±0.075)ng/m1]和PPAR-γ[(53.76±11.97)vs(35.12±9.66)vs(23.91±6.87)pg/ml]水平降低(P<0.05),且替米沙坦联合瑞舒伐他汀组上述指标较替米沙坦组下降更明显(P<0.05)。结论替米沙坦与他汀类药物联合应用可能改善T2DM合并冠心病患者血管的内皮损伤,为临床防治糖尿病早期冠状动脉粥样硬化提供了新的思路。
Objective To investigate the effect of telmisartan combined with rosuvastatin on the expression of serum hepatocyte growth factor (HGF), its receptor (c-met) and PPAR-γ in patients with T2DM complicated with coronary heart disease. Methods 95 cases of T2DM patients with coronary heart disease were divided into control group, telmisartan group and telmisartan combined with rosuvastatin group. The levels of serum HGF, c-met and PPAR-γ in each group were detected. Results Compared with the control group, HGF [(338.96 ± 36.51) vs (241.56 ± 29.88) vs (173.23 ± 32.25) pg / ml], telmisartan plus rosuvastatin group met [(0.657 ± 0.162) vs (0.489 + 0.093) vs (0.247 ± 0.075) ng / m1] and PPAR-γ [(53.76 ± 11.97) vs (35.12 ± 9.66 vs 23.91 ± 6.87 pg / ml] (P <0.05). Compared with telmisartan group, telmisartan combined with rosuvastatin decreased more significantly (P <0.05). Conclusion The combination of telmisartan and statins may improve endothelial injury in T2DM patients with coronary heart disease and provide a new idea for the prevention and treatment of early coronary atherosclerosis in patients with diabetes mellitus.